Poisons Amendment Regulation 2007 (No 1) (ACT)

In the case of Poisons Amendment Regulation 2007 (No 1) (ACT), the court was tasked with examining the validity and implications of the newly introduced regulations concerning the sale and record-keeping of pseudoephedrine. These regulations, which amended the Poisons Regulation 1933, introduced strict requirements for sellers to inform buyers about the mandatory record-keeping of pseudoephedrine sales, mandate specific details to be recorded, and allow buyers to access and request corrections to these records.

The primary legal issues addressed by the court involved the interpretation and application of the new regulatory provisions concerning the sale of pseudoephedrine. Key questions included the enforceability of the new record-keeping requirements, the scope of the information that must be recorded, and the procedures for buyers to access and challenge the accuracy of these records. The court also had to consider whether the penalties for non-compliance were justifiable within the regulatory framework.

The court found that the new regulations were consistent with the legislative intent to regulate the sale of pseudoephedrine more stringently to prevent its misuse. The court upheld the requirement for sellers to inform buyers of the record-keeping obligations and the details that must be recorded, emphasizing the importance of transparency and accountability in the sale of controlled substances. Regarding buyer access to records, the court supported the provisions allowing buyers to request access and corrections, highlighting the need for accurate record-keeping to facilitate regulatory oversight and enforcement. The court also deemed the penalties for non-compliance appropriate, given the public health implications of pseudoephedrine misuse.

The final orders of the court affirmed the validity of the Poisons Amendment Regulation 2007 (No 1) and its provisions, ensuring that the new regulations would come into effect as scheduled. The decision provided clarity on the obligations of sellers and the rights of buyers, contributing to a more regulated and transparent market for pseudoephedrine in the Australian Capital Territory.